1
|
Tarabichi S, Parvizi J. Preventing the Impact of Hyperglycemia and Diabetes on Patients Undergoing Total Joint Arthroplasty. Orthop Clin North Am 2023; 54:247-250. [PMID: 37271552 DOI: 10.1016/j.ocl.2023.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Primary and revision total joint arthroplasty (TJA) procedures have become increasingly popular worldwide. At the same time, a growing number of patients undergoing TJA are either known diabetics or exhibit evidence of hyperglycemia preoperatively. Based on extensive data, it is well-established that poor glycemic control in TJA patients is an independent risk factor for several complications, including periprosthetic joint infection and death. This article will serve as an overview of currently available evidence on how to prevent the impact of hyperglycemia and diabetes mellitus on patients undergoing TJA.
Collapse
Affiliation(s)
- Saad Tarabichi
- Rothman Orthopaedic Institute at Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Javad Parvizi
- Rothman Orthopaedic Institute at Thomas Jefferson University Hospital, Philadelphia, PA, USA.
| |
Collapse
|
2
|
Aihara M, Irie T, Yasukawa K, Minoura I, Miyauchi N, Nishi M, Katayama N, Yachiku K, Jinnouchi H, Kadowaki T, Yamauchi T, Yatomi Y, Kubota N, Sekimizu K. Development of a high-performance liquid chromatographic glycated albumin assay using finger-prick blood samples. Clin Chim Acta 2023; 542:117272. [PMID: 36858193 DOI: 10.1016/j.cca.2023.117272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Revised: 02/15/2023] [Accepted: 02/24/2023] [Indexed: 03/02/2023]
Abstract
BACKGROUND Home blood glucose monitoring can be effective for the self-management of diabetic patients. Hemoglobin A1c (HbA1c) is a widely used marker that reflects the average blood glucose within 1-2 months but does not sensitively respond to behavioral changes. Self-monitoring of blood glucose, continuous glucose monitoring, and flush glucose monitoring are sensitive; however, the cost and invasiveness of these tests prevent their widespread use. We focused on glycated albumin (GA), which reflects the average blood glucose levels over 1-2 weeks, and established a GA measurement method for self-sampling, finger-prick blood, which may be submitted for testing through postal service to receive weekly results. METHODS A high-performance liquid chromatography assay was established to measure GA levels in finger-prick blood samples from 103 diabetic patients and the results were compared with venous blood measurements using an enzymatic method. Furthermore, conditions for sending blood samples by mail were evaluated. Under these conditions, samples from 27 healthy and 32 patient volunteers sent through postal service were compared with samples stored in the laboratory. RESULTS GA levels were measured in samples containing > 20 μg albumin, which resulted in a CV less than 0.3%. The correlation between the GA levels of finger-prick blood measured using HPLC and the GA levels of venous blood measured using the enzymatic method was R2 = 0.988 with the slope ∼ 1.0, suggesting that the two were nearly equivalent. GA levels were stable for four days at 30 °C and two days at 37 °C. Mail-delivered samples exhibited a high correlation with samples that were not sent (R2 > 0.99). CONCLUSIONS We established a method to measure GA levels in self-sampled, finger-prick blood sent through postal service in Japan. The method is applicable for weekly feedback of GA levels, which is potentially useful for motivating behavioral changes. In addition to markers such as HbA1c and blood glucose, GA can be used as a marker for assessing dietary and physical activities. This study highlighted the importance of GA monitoring by developing a suitable measurement method for weekly monitoring of GA levels.
Collapse
Affiliation(s)
- Masakazu Aihara
- Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
| | - Tomoko Irie
- Provigate Inc., University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Keiko Yasukawa
- Department of Clinical Laboratory, The University of Tokyo Hospital, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Itsushi Minoura
- Provigate Inc., University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Noriko Miyauchi
- Provigate Inc., University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Mitsumi Nishi
- Provigate Inc., University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Norikazu Katayama
- Provigate Inc., University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Kenji Yachiku
- Provigate Inc., University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Hideaki Jinnouchi
- Jinnouchi Hospital, Kuhonji 6-2-3, Chuo-ku, Kumamoto 862-0976, Japan
| | - Takashi Kadowaki
- Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan; Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo 105-8470, Japan
| | - Toshimasa Yamauchi
- Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
| | - Yutaka Yatomi
- Department of Clinical Laboratory, The University of Tokyo Hospital, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Naoto Kubota
- Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
| | - Koshin Sekimizu
- Provigate Inc., University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
| |
Collapse
|
3
|
Reference intervals for glycated albumin during physiological pregnancy of Europid women: Evidences from a prospective observational study. Clin Chim Acta 2023; 541:117246. [PMID: 36754193 DOI: 10.1016/j.cca.2023.117246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 02/02/2023] [Accepted: 02/02/2023] [Indexed: 02/09/2023]
Abstract
BACKGROUND AND AIMS Glycated albumin (GA) may assess glycometabolic control over a short period of time respect to HbA1c, and its use to screen for gestational diabetes in pregnancy has been suggested. To this regard few data on reference intervals (RI) for GA on Europid women have been collected, only from cross-sectional investigations. Aim of this work has been to collect trimester-specific RI for GA in physiological pregnancies, following a longitudinal prospective study. METHODS Forty-five healthy pregnant Europid women have been enrolled for whom a GDM screening test was scheduled at 24-28 weeks, in 5 different Italian centers. Only those negative to the OGTT were included. The women had 4 successive visits at 6-10 weeks of gestation, at 16-18 weeks, at 24-28 weeks and at the end of pregnancy. ALT, AST, total bilirubin, C-reactive protein, cholinesterase, creatinine, GGT, glycated albumin, iron, total serum proteins, transferrin were measured in duplicate on aliquots of serum samples by a central laboratory. RESULTS The RI (2.5-97.5 percentiles) for GA were 11.1-14.8 % (I visit), 10.9-15.6 % (II visit), 10.6-14.1 % (III visit) and 10.7-14.3 % (IV visit). The RI of other biomarkers confirmed previously published data. The RI for serum cholinesterase we present are novel, and were 5049-9906 U/L (Iv), 4212-8965 U/L (IIv), 3518-8470 U/L (IIIv) and 3945-8727 U/L (IVv). CONCLUSIONS Trimester-specific RI are important for using GA and serum cholinesterase in pregnancy. However, considering the high inter-individual variability of both markers, the use of longitudinal interpretations of the individual variations of both proteins during pregnancy should be preferred.
Collapse
|
4
|
Divani M, Georgianos PI, Didangelos T, Liakopoulos V, Makedou K, Iliadis F, Savopoulos C, Grekas DM. Assessment of Hyperglycemia, Hypoglycemia and Inter-Day Glucose Variability Using Continuous Glucose Monitoring among Diabetic Patients on Chronic Hemodialysis. J Clin Med 2021; 10:jcm10184116. [PMID: 34575228 PMCID: PMC8465363 DOI: 10.3390/jcm10184116] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 09/08/2021] [Accepted: 09/09/2021] [Indexed: 12/21/2022] Open
Abstract
Continuous glucose monitoring (CGM) facilitates the assessment of short-term glucose variability and identification of acute excursions of hyper- and hypo-glycemia. Among 37 diabetic hemodialysis patients who underwent 7-day CGM with the iPRO2 device (Medtronic Diabetes, Northridge, CA, USA), we explored the accuracy of glycated albumin (GA) and hemoglobin A1c (HbA1c) in assessing glycemic control, using CGM-derived metrics as the reference standard. In receiver operating characteristic (ROC) analysis, the area under the curve (AUC) in diagnosing a time in the target glucose range of 70–180 mg/dL (TIR70–180) in <50% of readings was higher for GA (AUC: 0.878; 95% confidence interval (CI): 0.728–0.962) as compared to HbA1c (AUC: 0.682; 95% CI: 0.508–0.825) (p < 0.01). The accuracy of GA (AUC: 0.939; 95% CI: 0.808–0.991) in detecting a time above the target glucose range > 250 mg/dL (TAR>250) in >10% of readings did not differ from that of HbA1c (AUC: 0.854; 95% CI: 0.699–0.948) (p = 0.16). GA (AUC: 0.712; 95% CI: 0.539–0.848) and HbA1c (AUC: 0.740; 95% CI: 0.570–0.870) had a similarly lower efficiency in detecting a time below target glucose range < 70 mg/dL (TBR<70) in >1% of readings (p = 0.71). Although the mean glucose levels were similar, the coefficient of variation of glucose recordings (39.2 ± 17.3% vs. 32.0 ± 7.8%, p < 0.001) and TBR<70 (median (range): 5.6% (0, 25.8) vs. 2.8% (0, 17.9)) were higher during the dialysis-on than during the dialysis-off day. In conclusion, the present study shows that among diabetic hemodialysis patients, GA had higher accuracy than HbA1c in detecting a 7-day CGM-derived TIR70–180 < 50%. However, both biomarkers provided an imprecise reflection of acute excursions of hypoglycemia and inter-day glucose variability.
Collapse
Affiliation(s)
- Maria Divani
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece; (M.D.); (T.D.); (F.I.); (C.S.); (D.M.G.)
| | - Panagiotis I. Georgianos
- Hemodialysis Unit, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, 54626 Thessaloniki, Greece;
- Correspondence: ; Tel./Fax: +30-2313-303-844
| | - Triantafyllos Didangelos
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece; (M.D.); (T.D.); (F.I.); (C.S.); (D.M.G.)
| | - Vassilios Liakopoulos
- Hemodialysis Unit, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, 54626 Thessaloniki, Greece;
| | - Kali Makedou
- Laboratory of Biochemistry, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece;
| | - Fotios Iliadis
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece; (M.D.); (T.D.); (F.I.); (C.S.); (D.M.G.)
| | - Christos Savopoulos
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece; (M.D.); (T.D.); (F.I.); (C.S.); (D.M.G.)
| | - Dimitrios M. Grekas
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece; (M.D.); (T.D.); (F.I.); (C.S.); (D.M.G.)
| |
Collapse
|
5
|
Peer N, George J, Lombard C, Levitt N, Kengne AP. Associations of glycated albumin and fructosamine with glycaemic status in urban black South Africans. Clin Chim Acta 2021; 519:291-297. [PMID: 34022245 DOI: 10.1016/j.cca.2021.05.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 05/17/2021] [Accepted: 05/18/2021] [Indexed: 11/15/2022]
Abstract
BACKGROUND The associations of glycated albumin (GA) and fructosamine (FA) as alternate tests for diabetes screening in South Africans were examined to overcome shortcomings with oral glucose tolerance tests (OGTTs). METHODS Based on OGTTs, glycaemic status included 1) normal glucose, 2) dysglycaemia (impaired fasting glucose, impaired glucose tolerance, newly diagnosed diabetes), and 3) known diabetes. RESULTS Among 1092 participants, >21 years, mean GA (16.9%) and FA (230.2 μmol/l) increased significantly by age and worsening glycaemic status and were significantly higher in women vs. men and BMI (kg/m2) ≥ 30 vs. <30. For dysglycaemia, correlations of GA and FA with fasting and 2-hour glucose levels were higher in obese (0.576 to 0.688) vs. non-obese (-0.010 to 0.522). Optimal GA threshold to identify dysglycaemia was 15.35% and comparable, but with lower sensitivity (0.54) and specificity (0.55), to Asian studies. For FA, the optimal cut-point of 227.0 μmol/l approximated that described in the literature. Dysglycaemia and known diabetes were associated with GA, while only known diabetes was related to FA, in models adjusted for age, gender and obesity. CONCLUSIONS Potential exists for GA and/or FA as alternative measures of dysglycaemia in clinical practice in Africans, but longitudinal studies are required to clearly elucidate their utility.
Collapse
Affiliation(s)
- Nasheeta Peer
- Non-communicable Diseases Research Unit, South African Medical Research Council, Durban and Cape Town, South Africa; Department of Medicine, University of Cape Town, Cape Town, South Africa.
| | - Jaya George
- Department of Chemical Pathology, University of the Witwatersrand, and National Health Laboratory Services, Johannesburg, South Africa
| | - Carl Lombard
- Biostatistics Unit, South African Medical Research Council, Cape Town, South Africa
| | - Naomi Levitt
- Chronic Disease Initiative for Africa, Department of Medicine, UCT, Cape Town, South Africa
| | - Andre-Pascal Kengne
- Non-communicable Diseases Research Unit, South African Medical Research Council, Durban and Cape Town, South Africa; Department of Medicine, University of Cape Town, Cape Town, South Africa
| |
Collapse
|
6
|
Ricós C, Fernández-Calle P, Gonzalez-Lao E, Simón M, Díaz-Garzón J, Boned B, Marqués-García F, Minchinela J, Perich MC, Tejedor-Ganduxé X, Corte Z, Aarsand AK, Aslan B, Carobene A, Coskun A, Sandberg S. Evaluación crítica y meta-análisis de estudios de variación biológica para albúmina glicosilada, glucosa y HbA 1c. ADVANCES IN LABORATORY MEDICINE 2020; 1:20200040. [PMCID: PMC10197261 DOI: 10.1515/almed-2020-0040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Accepted: 04/15/2020] [Indexed: 06/28/2023]
Abstract
Objetivos A lo largo de los años se han publicado numerosos artículos sobre variación biológica (VB) de diferente calidad. Los objetivos de este trabajo fueron realizar una revisión sistemática y una evaluación crítica de los estudios de VB para albúmina glicosilada y proporcionar datos actualizados de VB para glucosa y HbA1c, incluyendo prestigiosos estudios recientemente publicados como el Estudio de Variación Biológica Europea (EuBIVAS). Métodos Se hizo una búsqueda bibliográfica sistemática para identificar estudios sobre VB, encontrándose 9 estudios no incluidos en la primera revisión: 4 para albúmina glicosilada, 3 para glucosa y 3 para HbA1c. Se realizó una evaluación crítica de los estudios relevantes, utilizando la herramienta Biological Variation Data Critical Appraisal Checklist (BIVAC). Se obtuvieron los estimados globales de VB mediante meta-análisis de los estudios que cumplían los requisitos BIVAC, realizados en individuos sanos con estudios de diseño similar. Resultados Un estudio recibió el grado A, dos el B y 6 el C. en la mayoría de los casos el grado C se asoció a deficiencias en el análisis estadístico de los datos. Los estimados de VB para albúmina glicosilada fueron: CVI = 1,4%(1,2–2,1) y CVG = 5,7%(4,7–10,6); para HbA1c, CVI = 1,2%(0,3–2,5), CVG = 5,4%(3,3–7,3) y para glucosa, CVI = 5,0%(4,1–12,0), CVG = 8,1%(2,7–10,8) no difirieron de los estimados globales previamente descritos. Conclusiones La evaluación crítica y clasificación de los estudios de VB a tenor de su calidad metodológica, seguido de un meta-análisis, genera estimados de VB robustos y fiables. Este estudio proporciona datos de VB para albúmina glicolisada, glucosa y HbA1c actualizados y basados en la evidencia científica.
Collapse
Affiliation(s)
- Carmen Ricós
- Spanish Society of Laboratory Medicine (SEQCML), Analytical Quality Commission, Padilla, 323, Barcelona, España
| | - Pilar Fernández-Calle
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, Task Group on Biological Variation Database, Madrid, España
- EFLM, Working Group on Biological Variation, Madrid, España
- Hospital Universitario La Paz, Madrid, España
| | - Elisabet Gonzalez-Lao
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, Task Group on Biological Variation Database, Madrid, España
- Quality Healthcare, Grupo ACMS, Madrid, España
| | - Margarida Simón
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, Task Group on Biological Variation Database, Vilafranca del Penedes, España
- Consortium of Laboratory Intercomarcal Alt Penedès and Garraf l’Anoia, Vilafranca del Penedes, España
| | - Jorge Díaz-Garzón
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, Task Group on Biological Variation Database, Madrid, España
- EFLM, Working Group on Biological Variation, Madrid, España
- Hospital Universitario La Paz, Madrid, España
| | - Beatriz Boned
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, Task Group on Biological Variation Database, Madrid, España
- Hospital Royo Villanova, Zaragoza, España
| | - Fernando Marqués-García
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, Task Group on Biological Variation Database, Salamanca, España
- Hospital Universitario de Salamanca, Salamanca, España
| | - Joana Minchinela
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, TaskGroup on Biological Variation Database, Badalona, España
- Hospital Germans Trias i Pujol, Badalona, España
| | - Maria Carmen Perich
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, Task Group on Biological Variation Database, Barcelona, España
- Hospital Vall d’Hebron, Barcelona, España
| | - Xavier Tejedor-Ganduxé
- SEQCML, Analytical Quality Commission, Barcelona, España
- EFLM, TaskGroup on Biological Variation Database, Badalona, España
- Hospital Germans Trias i Pujol, Badalona, España
| | - Zoraida Corte
- SEQCML, Analytical Quality Commission, Barcelona, España
- Hospital Universitario San Agustin, Aviles, España
| | - Aasne K. Aarsand
- EFLM, Task Group on Biological Variation Database, Bergen, Norway
- EFLM, Working Group on Biological Variation, Bergen, Norway
- Haukeland University Hospital, Bergen, Norway
- Norwegian Quality Improvement of Laboratory Examinations, Haraldplass Deaconess Hospital, Bergen, Norway
| | - Berna Aslan
- EFLM, Task Group on Biological Variation Database, Toronto, Canada
- Institute for Quality Management in Healthcare of Canada, Toronto, Canada
| | - Anna Carobene
- EFLM, Task Group on Biological Variation Database, Milan, Italy
- EFLM, Working Group on Biological Variation, Milan, Italy
- Laboratory Medicine, Ospedale San Raffaele, Milan, Italy
| | - Abdurrahman Coskun
- EFLM, Task Group on Biological Variation Database, Istanbul, Turkey
- EFLM, Working Group on Biological Variation, Istanbul, Turkey
- Acibadem Universitesi, Istanbul, Turkey
| | - Sverre Sandberg
- EFLM, Task Group on Biological Variation Database, Bergen, Norway
- EFLM, Working Group on Biological Variation, Bergen, Norway
- Department of Global Public Health, Bergen, Norway
| |
Collapse
|
7
|
Ricós C, Fernández-Calle P, Gonzalez-Lao E, Simón M, Díaz-Garzón J, Boned B, Marqués-García F, Minchinela J, Perich MC, Tejedor-Ganduxé X, Corte Z, Aarsand AK, Aslan B, Carobene A, Coskun A, Sandberg S. Critical appraisal and meta-analysis of biological variation studies on glycosylated albumin, glucose and HbA 1c. ADVANCES IN LABORATORY MEDICINE 2020; 1:20200029. [PMID: 37361503 PMCID: PMC10197502 DOI: 10.1515/almed-2020-0029] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Accepted: 04/15/2020] [Indexed: 06/28/2023]
Abstract
OBJECTIVES Numerous biological variation (BV) studies have been performed over the years, but the quality of these studies vary. The objectives of this study were to perform a systematic review and critical appraisal of BV studies on glycosylated albumin and to deliver updated BV estimates for glucose and HbA1c, including recently published high-quality studies such as the European Biological Variation study (EuBIVAS). METHODS Systematic literature searches were performed to identify BV studies. Nine publications not included in a previous review were identified; four for glycosylated albumin, three for glucose, and three for HbA1c. Relevant studies were appraised by the Biological Variation Data Critical Appraisal Checklist (BIVAC). Global BV estimates were derived by meta-analysis of BIVAC-compliant studies in healthy subjects with similar study design. RESULTS One study received BIVAC grade A, 2B, and 6C. In most cases, the C-grade was associated with deficiencies in statistical analysis. BV estimates for glycosylated albumin were: CVI=1.4% (1.2-2.1) and CVG=5.7% (4.7-10.6), whereas estimates for HbA1c, CVI=1.2% (0.3-2.5), CVG=5.4% (3.3-7.3), and glucose, CVI=5.0% (4.1-12.0), CVG=8.1% (2.7-10.8) did not differ from previously published global estimates. CONCLUSIONS The critical appraisal and rating of BV studies according to their methodological quality, followed by a meta-analysis, generate robust, and reliable BV estimates. This study delivers updated and evidence-based BV estimates for glycosylated albumin, glucose and HbA1c.
Collapse
Affiliation(s)
- Carmen Ricós
- Spanish Society of Laboratory Medicine (SEQC), Analytical Quality Commission, Barcelona, Spain
- Padilla, 323, Barcelona 08035, Spain
| | - Pilar Fernández-Calle
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, Task Group on Biological Variation Database; EFLM, Working Group on Biological Variation; and Hospital Universitario La Paz, Madrid, Spain
| | - Elisabet Gonzalez-Lao
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, Task Group on Biological Variation Database; and Quality Healthcare, Grupo ACMS, Madrid, Spain
| | - Margarida Simón
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, Task Group on Biological Variation Database; and Consortiumof Laboratory Intercomarcal Alt Penedès and Garraf l’Anoia, Vilafranca del Penedes, Spain
| | - Jorge Díaz-Garzón
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, Task Group on Biological Variation Database; EFLM, Working Group on Biological Variation; and Hospital Universitario La Paz, Madrid, Spain
| | - Beatriz Boned
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, TaskGroup on Biological Variation Database; and Hospital Royo Villanova, Zaragoza, Spain
| | - Fernando Marqués-García
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, Task Group on Biological Variation Database; and Hospital Universitario de Salamanca, Salamanca, Spain
| | - Joana Minchinela
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, TaskGroup on Biological VariationDatabase; and Hospital Germans Trias i Pujol, Badalona, Spain
| | - Maria Carmen Perich
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, Task Group on Biological Variation Database; and Hospital Vall d’Hebron, Barcelona, Spain
| | - Xavier Tejedor-Ganduxé
- SEQC, Analytical Quality Commission, Barcelona, Spain
- EFLM, Task Group on Biological Variation Database; and Hospital Germans Trias i Pujol, Badalona, Spain
| | - Zoraida Corte
- SEQC, Analytical Quality Commission, Barcelona, Spain
- Hospital Universitario San Agustin, Aviles, Spain
| | - Aasne K. Aarsand
- EFLM, Task Group on Biological Variation Database; EFLM, Working Group on Biological Variation; Haukeland University Hospital, Bergen, Norway
- Norwegian Quality Improvement of Laboratory Examinations, Haraldplass Deaconess Hospital, Bergen, Norway
| | - Berna Aslan
- EFLM, Task Group on Biological Variation Database; Institute for Quality Management in Healthcare of Canada, Toronto, Canada
| | - Anna Carobene
- EFLM, Task Group on Biological Variation Database; EFLM,Working Group on Biological Variation; and LaboratoryMedicine, Ospedale San Raffaele, Milan, Italy
| | - Abdurrahman Coskun
- EFLM, Task Group on Biological Variation Database; EFLM, Working Group on Biological Variation; and Acibadem Universitesi, Istanbul, Turkey
| | - Sverre Sandberg
- EFLM, Task Group on Biological Variation Database; EFLM,Working Group on Biological Variation; and Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
| |
Collapse
|
8
|
Bergman M, Abdul-Ghani M, DeFronzo RA, Manco M, Sesti G, Fiorentino TV, Ceriello A, Rhee M, Phillips LS, Chung S, Cravalho C, Jagannathan R, Monnier L, Colette C, Owens D, Bianchi C, Del Prato S, Monteiro MP, Neves JS, Medina JL, Macedo MP, Ribeiro RT, Filipe Raposo J, Dorcely B, Ibrahim N, Buysschaert M. Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract 2020; 165:108233. [PMID: 32497744 PMCID: PMC7977482 DOI: 10.1016/j.diabres.2020.108233] [Citation(s) in RCA: 96] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 05/19/2020] [Indexed: 02/07/2023]
Abstract
Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.
Collapse
Affiliation(s)
- Michael Bergman
- NYU School of Medicine, NYU Diabetes Prevention Program, Endocrinology, Diabetes, Metabolism, VA New York Harbor Healthcare System, Manhattan Campus, 423 East 23rd Street, Room 16049C, NY, NY 10010, USA.
| | - Muhammad Abdul-Ghani
- Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
| | - Ralph A DeFronzo
- Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
| | - Melania Manco
- Research Area for Multifactorial Diseases, Bambino Gesù Children Hospital, Rome, Italy.
| | - Giorgio Sesti
- Department of Clinical and Molecular Medicine, University of Rome Sapienza, Rome 00161, Italy
| | - Teresa Vanessa Fiorentino
- Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Catanzaro 88100, Italy.
| | - Antonio Ceriello
- Department of Cardiovascular and Metabolic Diseases, Istituto Ricerca Cura Carattere Scientifico Multimedica, Sesto, San Giovanni (MI), Italy.
| | - Mary Rhee
- Emory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA.
| | - Lawrence S Phillips
- Emory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA.
| | - Stephanie Chung
- Diabetes Endocrinology and Obesity Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
| | - Celeste Cravalho
- Diabetes Endocrinology and Obesity Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
| | - Ram Jagannathan
- Emory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA.
| | - Louis Monnier
- Institute of Clinical Research, University of Montpellier, Montpellier, France.
| | - Claude Colette
- Institute of Clinical Research, University of Montpellier, Montpellier, France.
| | - David Owens
- Diabetes Research Group, Institute of Life Science, Swansea University, Wales, UK.
| | - Cristina Bianchi
- University Hospital of Pisa, Section of Metabolic Diseases and Diabetes, University Hospital, University of Pisa, Pisa, Italy.
| | - Stefano Del Prato
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
| | - Mariana P Monteiro
- Endocrine, Cardiovascular & Metabolic Research, Unit for Multidisciplinary Research in Biomedicine (UMIB), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
| | - João Sérgio Neves
- Department of Surgery and Physiology, Cardiovascular Research and Development Center, Faculty of Medicine, University of Porto, Porto, Portugal; Department of Endocrinology, Diabetes and Metabolism, São João University Hospital Center, Porto, Portugal.
| | | | - Maria Paula Macedo
- CEDOC-Centro de Estudos de Doenças Crónicas, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal; APDP-Diabetes Portugal, Education and Research Center (APDP-ERC), Lisboa, Portugal.
| | - Rogério Tavares Ribeiro
- Institute for Biomedicine, Department of Medical Sciences, University of Aveiro, APDP Diabetes Portugal, Education and Research Center (APDP-ERC), Aveiro, Portugal.
| | - João Filipe Raposo
- CEDOC-Centro de Estudos de Doenças Crónicas, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal; APDP-Diabetes Portugal, Education and Research Center (APDP-ERC), Lisboa, Portugal.
| | - Brenda Dorcely
- NYU School of Medicine, Division of Endocrinology, Diabetes, Metabolism, NY, NY 10016, USA.
| | - Nouran Ibrahim
- NYU School of Medicine, Division of Endocrinology, Diabetes, Metabolism, NY, NY 10016, USA.
| | - Martin Buysschaert
- Department of Endocrinology and Diabetology, Université Catholique de Louvain, University Clinic Saint-Luc, Brussels, Belgium.
| |
Collapse
|
9
|
Chen L, Zhang B, Yang L, Lou J, Jiang Y, Zhang S. Individualized Correction of the Interference of Hemolysis on Glycated Albumin Determined by the Ketamine Oxidase Method. Lab Med 2020; 51:151-156. [PMID: 31352488 DOI: 10.1093/labmed/lmz042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
OBJECTIVE To investigate the effect of hemolysis on glycated albumin (GA) levels, as determined by the ketamine oxidase method. METHODS GA levels and the hemolysis index were determined in nonhemolyzed serum and hemolyzed serum from corresponding patients. We developed an equation to correct the interference of hemolysis on GA, using multiple regression analysis. RESULTS The degree of hemolysis was negatively correlated with GA levels (R2 = 0.9500). A correction equation for GA (corrected GA = 2.703 × OD of hemolysis + 1.044 × measured GA -0.906) can revert GA concentrations of hemolyzed specimens to values that were not significantly different from the GA concentration of corresponding nonhemolyzed specimens. The bias of GA concentrations before and after correction was statistically significantly different (P <.01). CONCLUSIONS Our results indicate that the level of GA measured through the ketamine oxidase method is negatively affected by hemolysis. The individualized correction of GA results provides increased accuracy in hemolyzed specimens.
Collapse
Affiliation(s)
- Li Chen
- Department of Obstetrics, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Bingfeng Zhang
- Department of Laboratory Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Lu Yang
- Department of Laboratory Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Jianfang Lou
- Department of Laboratory Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Ye Jiang
- Department of Laboratory Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Shichang Zhang
- Department of Obstetrics, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|
10
|
Zendjabil M. Glycated albumin. Clin Chim Acta 2020; 502:240-244. [DOI: 10.1016/j.cca.2019.11.007] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 10/30/2019] [Accepted: 11/04/2019] [Indexed: 12/14/2022]
|
11
|
Bellia C, Cosma C, Lo Sasso B, Bivona G, Agnello L, Zaninotto M, Ciaccio M. Glycated albumin as a glycaemic marker in patients with advanced chronic kidney disease and anaemia: a preliminary report. Scandinavian Journal of Clinical and Laboratory Investigation 2019; 79:293-297. [PMID: 31070491 DOI: 10.1080/00365513.2019.1613673] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Background: The association between glycated albumin (GA) and glycaemic status has not been fully described in patients with advanced chronic kidney disease (CKD) in relation to anaemia. The aim of this study was to evaluate the relationship between GA and fasting plasma glucose (FPG) and HbA1c in patients with advanced CKD and to evaluate the influence of anaemia in such relationship. Materials and methods: Patients with CKD stage 4 or 5 were included in the study. eGFR was calculated by the CKD-EPI creatinine equation. Plasma GA was measured by an enzymatic method. Results: Eighty-one patients were included in the study, 46 (57%) were males; the mean age was 67 ± 14 years. HbA1c was correlated with Hb (r = 0.39; p = .0003), and no significant correlation was detected between plasma GA and serum albumin (p = .82). A significant association between FPG and GA (r2 = 0.41; p < .0001), and between FPG and HbA1c (r2 = 0.42; p < .0001) was detected in the whole study population. Patients with moderate/severe anaemia had lower HbA1c than patients with no anaemia, while both FPG and GA were comparable between the two groups. Multivariate regression analysis showed that GA was a significant predictor of FPG in patients with moderate/severe anaemia while HbA1c did not (r2 = 0.55; p < .0001 for the model). Conclusions: GA, alone or in combination with other biomarkers, can be considered for the evaluation of glycaemic status in patients with advanced CKD and severe anaemia.
Collapse
Affiliation(s)
- Chiara Bellia
- a Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo , Palermo , Italy
| | - Chiara Cosma
- b Department of Laboratory Medicine, University-Hospital , Padova , Italy
| | - Bruna Lo Sasso
- a Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo , Palermo , Italy
| | - Giulia Bivona
- a Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo , Palermo , Italy
| | - Luisa Agnello
- a Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo , Palermo , Italy
| | - Martina Zaninotto
- b Department of Laboratory Medicine, University-Hospital , Padova , Italy
| | - Marcello Ciaccio
- a Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo , Palermo , Italy.,c Department of Laboratory Medicine, University-Hospital , Palermo , Italy
| |
Collapse
|
12
|
Glycated serum proteins: High in pancreatic cancer and low in preeclampsia. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2019; 162:321-333. [PMID: 30905460 DOI: 10.1016/bs.pmbts.2019.01.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Glycated serum protein (GSP, measured as serum fructosamine concentration in μmol/L) is a product of glycation reaction between glucose and serum proteins in the blood circulation. GSP is used along with blood glucose, glycated hemoglobin (HbA1c), and glycated albumin as indicators of glycemic control for diabetic patients. However, a systematic comparison of the GSP levels in different types of human diseases has not been reported. In this study, 62,698 clinical lab test results of GSP levels in patients with 61 clinically defined diseases over the past 5 years in our hospital were retrieved and compared to that of 1861 clinical lab test results in healthy individuals. Based on the mean (SD), median, and p (-Log10p) values, we found that patients with type 2 diabetes, hepatic encephalopathy, pancreatic cancer, healthy individuals >65 years old, and cerebral arteriosclerosis had significantly (p<0.05, -Log10p>1.30) increased whereas patients with 49/61 diseases including preeclampsia, nephrotic syndrome, sepsis, lupus erythematous, and leukemia had significantly decreased GSP levels compared to that of healthy controls. Among the 61 diseases, type 2 diabetes and leukemia had the highest -Log10p values (>274) and lupus erythematous, nephrotic syndrome, and gastric cancer had -Log10p values >140. Revealing the molecular mechanisms especially those underlying the decreased GSP levels in most of human diseases might make GSP levels serve more clinical purposes in future.
Collapse
|
13
|
Liang L, He H, Zeng Y, Zhang M, Wang X, Li X, Liang S, An Z, Huang H. Evaluation of biological variation of glycated hemoglobin and glycated albumin in healthy Chinese subjects. J Clin Lab Anal 2018; 33:e22715. [PMID: 30461058 PMCID: PMC6587440 DOI: 10.1002/jcla.22715] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 10/07/2018] [Accepted: 10/18/2018] [Indexed: 02/05/2023] Open
Abstract
Background Glycated hemoglobin (HbA1c) and glycated serum albumin (GSA) are used to evaluate the mean blood glucose levels. To ensure safe clinical application of HbA1c and GSA, reliable biological variation (BV) data are required. The aim of this research was to define the BV of HbA1c and GSA employing stringent rules. Methods Blood samples were drawn from 19 healthy subjects (10 females, nine males) once per week for 5 weeks. All samples were analyzed using enzymatic method for GSA and HPLC for HbA1c. The data were assessed for outliers, normality and variance homogeneity, and coefficient of variation (by ANOVA) for BV. Sex‐stratified BV including within‐subject (CVI) and between‐subject (CVG) was defined for HbA1c and GSA. Results The following estimates for BV values for CVI and CVG, respectively, were GSA: 1.23% and 4.67%, Alb: 0.75% and 3.18%, and HbA1c: 0.12% and 2.91%. The RCV of GSA was 3.61%, and HbA1c was 1.41%. And the II was 0.26 for GSA, and 0.07 for HbA1c, both of them less than 0.6. According to the 95% CI, the CVI of HbA1c was statistically different between females and males. And both the CVG of HbA1c and GSA were statistically different between females and males. Conclusion All CVI and CVG estimates were lower than those reported in the online BV database. And there is a significant difference between males and females. Analytical performance specifications derived from BV of this research can be applied internationally.
Collapse
Affiliation(s)
- Libo Liang
- International Medical Centre, West China Hospital of Sichuan University, Chengdu, China
| | - He He
- Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
| | - Yuping Zeng
- Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
| | - Mei Zhang
- Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
| | - Xia Wang
- Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
| | - Xiaoling Li
- Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
| | - Shanshan Liang
- Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
| | - Zhenmei An
- Department of Endocrine and Metabolism, West China Hospital of Sichuan University, Chengdu, China
| | - Hengjian Huang
- Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
| |
Collapse
|
14
|
Zemlin AE, Barkhuizen M, Kengne AP, Erasmus RT, Matsha TE. Performance of glycated albumin for type 2 diabetes and prediabetes diagnosis in a South African population. Clin Chim Acta 2018; 488:122-128. [PMID: 30395867 DOI: 10.1016/j.cca.2018.11.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 10/19/2018] [Accepted: 11/01/2018] [Indexed: 12/15/2022]
Abstract
OBJECTIVE To assess the utility of glycated albumin (GA%) as a diagnostic marker of type 2 diabetes and prediabetes in an African population. METHODS GA% levels were determined in a sample of 1294 mixed ancestry adults (74.2% women) residing in Cape Town using an enzymatic method. The participants' glycemic status was based on oral glucose tolerance test (OGTT). RESULTS The mean age was 47.8 years with a mean body mass index (BMI) of 28.7 kg/m2. Obesity was more pronounced in the screen-detected diabetes and prediabetes groups with mean BMI's of 32.5 kg/m2 and 31.5 kg/m2 respectively. The optimal thresholds of GA% to diagnose screen-detected diabetes and prediabetes, were 14.90% and 12.75% respectively. For screen-detected diabetes, the C-statistic was higher for HbA1c than GA% (p = .034) with values of 0.899 (95% CI 0.855-0.943) and 0.873 (0.782-0.892) respectively. The agreement between GA% and HbA1c at their optimal thresholds for diagnosing screen-detected diabetes, was kappa = 0.33 (95% CI 0.26-0.40) and was higher than the agreement for prediabetes, kappa = 0.16 (0.11-0.21). The performance of GA% to identify screen-detected diabetes at the optimal threshold of 14.90%, was 64.8% (95% CI 54.1%-74.6%) for sensitivity and 93.5% (92.0%-94.9%) for specificity. GA% was significantly less sensitive, but more specific than HbA1c (at the optimal threshold of 6.15%) for screen-detected diabetes diagnosis (both p ≤ .002 from McNemar tests for sensitivity and specificity comparisons). CONCLUSIONS GA% performed less well than HbA1c to identify participants with OGTT-diagnosed type 2 diabetes or prediabetes (HbA1c cut-off of 6.15% and 5.95% respectively) in this population.
Collapse
Affiliation(s)
- Annalise E Zemlin
- Department of Pathology, Chemical Pathology Division, National Health Laboratory Service (NHLS) and University of Stellenbosch, Tygerberg Hospital, Cape Town, South Africa.
| | - Marizna Barkhuizen
- Department of Pathology, Chemical Pathology Division, National Health Laboratory Service (NHLS) and University of Stellenbosch, Tygerberg Hospital, Cape Town, South Africa
| | - Andre P Kengne
- Department of Medicine, Faculty of Health Science, University of Cape Town, Observatory, South Africa; Non-Communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa
| | - Rajiv T Erasmus
- Department of Pathology, Chemical Pathology Division, National Health Laboratory Service (NHLS) and University of Stellenbosch, Tygerberg Hospital, Cape Town, South Africa
| | - Tandi E Matsha
- Department of Biomedical Sciences, Cape Peninsula University of Technology, South Africa.
| |
Collapse
|
15
|
Divani M, Georgianos PI, Didangelos T, Iliadis F, Makedou A, Hatzitolios A, Liakopoulos V, Grekas DM. Comparison of Glycemic Markers in Chronic Hemodialysis Using Continuous Glucose Monitoring. Am J Nephrol 2017; 47:21-29. [PMID: 29275415 DOI: 10.1159/000485843] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2017] [Accepted: 11/29/2017] [Indexed: 12/17/2022]
Abstract
BACKGROUND Glycated hemoglobin A1c (HbA1c) among diabetic hemodialysis patients continues to be the standard of care, although its limitations are well recognized. This study evaluated glycated albumin (GA) and glycated serum protein (GSP) as alternatives to HbA1c in detecting glycemic control among diabetic hemodialysis patients using continuous-glucose-monitoring (CGM)-derived glucose as reference standard. METHODS A CGM system (iPRO) was applied for 7 days in 37 diabetic hemodialysis patients to determine glycemic control. The accuracy of GA and GSP versus HbA1c in detecting a 7-day average glucose ≥184 mg/dL was evaluated via receiver-operating-characteristic (ROC) analysis. RESULTS CGM-derived glucose exhibited strong correlation (r = 0.970, p < 0.001) and acceptable agreement with corresponding capillary glucose measurements obtained by the patients themselves in 1,169 time-points over the 7-day-long CGM. The area under ROC curve (AUC) for GA, GSP, and HbA1c to detect poor glycemic control was 0.976 (0.862-1.000), 0.682 (0.502-0.862), and 0.776 (0.629-0.923) respectively. GA levels >20.3% had 90.9% sensitivity and 96.1% specificity in detecting a 7-day average glucose ≥184 mg/dL. The AUC for GA was significantly higher than the AUC for GSP (difference between areas: 0.294, p < 0.001) and the AUC for HbA1c (difference between areas: 0.199, p < 0.01). CONCLUSION Among diabetic hemodialysis patients, GA is a stronger indicator of poor glycemic control assessed with 7-day-long CGM when compared to GSP and HbA1c.
Collapse
Affiliation(s)
- Maria Divani
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Panagiotis I Georgianos
- Hemodialysis Unit, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Triantafyllos Didangelos
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Fotios Iliadis
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Areti Makedou
- Laboratory for Lipids and CVD prevention, 2nd Department of Pediatrics, AHEPA Hospital, Aristotle University of ThessalonikiGreece, Thessaloniki, Greece
| | - Apostolos Hatzitolios
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Vassilios Liakopoulos
- Hemodialysis Unit, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Dimitrios M Grekas
- 1st Propedeutic Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| |
Collapse
|
16
|
Bellia C, Zaninotto M, Cosma C, Agnello L, Lo Sasso B, Bivona G, Plebani M, Ciaccio M. Definition of the upper reference limit of glycated albumin in blood donors from Italy. ACTA ACUST UNITED AC 2017; 56:120-125. [DOI: 10.1515/cclm-2017-0179] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 04/24/2017] [Indexed: 11/15/2022]
Abstract
Abstract
Background:
Glycated Albumin (GA) has been proposed as a short-term indicator of glycemic homeostasis. The aim of this study is to describe the distribution of GA in a large sample of blood donors from Italy to evaluate whether demographic features, namely age and sex, could influence GA levels and define specific reference limits.
Methods:
The study included 1334 Italian blood donors. GA was measured using an enzymatic method (quantILab Glycated Albumin, IL Werfen, Germany). The upper reference limit (URL) was calculated using the non-parametric percentile method.
Results:
A modest, although significant, increase of GA was observed in relation to age (p<0.001), especially in males, where the differences were more pronounced (p<0.001 in males, p=0.003 in females). Slight differences were documented based on sex (12% [11.3–12.8] in males; 12.2% [11.4–13.1] in females; p=0.01). After excluding individuals with fasting plasma glucose ≥7 mmol/L, the calculated GA URL was 14.5% (95% CI: 14.3–14.7). Subjects with GA>14.5% presented a mean age of 48.4±12.2 years, 66.7% were males and the mean glucose was 6.88±2.5 mmol/L.
Conclusions:
GA in Caucasians shows a similar increasing trend at older ages documented in other ethnicities. The definition of the URL in this population could be useful for both clinical studies, which will clarify the role of GA for diagnosing and monitoring diabetes, and will encourage the introduction of GA in clinical practice.
Collapse
Affiliation(s)
- Chiara Bellia
- Department of Biopathology and Medical Biotechnologies , Section of Clinical Biochemistry and Clinical Molecular Medicine , University of Palermo , Palermo , Italy
| | - Martina Zaninotto
- Department of Laboratory Medicine , University-Hospital , Padova , Italy
| | - Chiara Cosma
- Department of Laboratory Medicine , University-Hospital , Padova , Italy
| | - Luisa Agnello
- Department of Biopathology and Medical Biotechnologies , Section of Clinical Biochemistry and Clinical Molecular Medicine , University of Palermo , Palermo , Italy
| | - Bruna Lo Sasso
- Department of Biopathology and Medical Biotechnologies , Section of Clinical Biochemistry and Clinical Molecular Medicine , University of Palermo , Palermo , Italy
| | - Giulia Bivona
- Department of Biopathology and Medical Biotechnologies , Section of Clinical Biochemistry and Clinical Molecular Medicine , University of Palermo , Palermo , Italy
| | - Mario Plebani
- Department of Laboratory Medicine , University-Hospital , Padova , Italy
| | - Marcello Ciaccio
- Department of Biopathology and Medical Biotechnologies , Section of Clinical Biochemistry and Clinical Molecular Medicine , University of Palermo , Palermo , Italy
- Department of Laboratory Medicine , University-Hospital , Palermo , Italy
| |
Collapse
|
17
|
Freitas PAC, Ehlert LR, Camargo JL. Glycated albumin: a potential biomarker in diabetes. ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2017; 61:296-304. [PMID: 28699985 PMCID: PMC10118799 DOI: 10.1590/2359-3997000000272] [Citation(s) in RCA: 91] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Accepted: 02/13/2017] [Indexed: 11/22/2022]
Abstract
Diabetes mellitus (DM) is a chronic and metabolic disease that presents a high global incidence. Glycated hemoglobin (A1C) is the reference test for long-term glucose monitoring, and it exhibits an association with diabetic chronic complications. However, A1C is not recommended in clinical situations which may interfere with the metabolism of hemoglobin, such as in hemolytic, secondary or iron deficiency anemia, hemoglobinopathies, pregnancy, and uremia. The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. GA is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform. These laboratory characteristics have ensured the highlight of GA in studies from the last decade, as a marker of monitoring and screening for DM, as well as a predictor of long-term outcomes of the disease. The aim of this review was to discuss the physiological and biochemistry characteristics of the GA, as well as its clinical utility in DM.
Collapse
Affiliation(s)
| | | | - Joíza Lins Camargo
- Universidade Federal do Rio Grande do Sul, Brasil; Hospital de Clínicas de Porto Alegre, Brasil
| |
Collapse
|
18
|
Ingram T, Zuck J, Borges CR, Redig P, Sweazea KL. Variations in native protein glycation and plasma antioxidants in several birds of prey. Comp Biochem Physiol B Biochem Mol Biol 2017; 210:18-28. [PMID: 28529085 DOI: 10.1016/j.cbpb.2017.05.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Revised: 05/03/2017] [Accepted: 05/09/2017] [Indexed: 12/23/2022]
Abstract
Birds are an anomaly among vertebrates as they are remarkably long-lived despite having naturally high blood glucose and metabolic rates. For mammals, hyperglycemia leads to oxidative stress and protein glycation. In contrast, many studies have shown that domestic and wild birds are relatively resistant to these glucose-mediated pathologies. Surprisingly very little research has examined protein glycation in birds of prey, which by nature consume a diet high in protein and fat that promotes gluconeogenesis. The purpose of this study was to evaluate protein glycation and antioxidant concentrations in serum samples from several birds of prey (bald eagle (BAEA), red-tailed hawk (RTHA), barred owl (BAOW), great horned owl (GHOW)) as protein glycation can accelerate oxidative stress and vice versa. Serum glucose was measured using a commercially available assay, native albumin glycation was measured by mass spectrometry and various antioxidants (uric acid, vitamin E, retinol and several carotenoids) were measured by high performance liquid chromatography. Although glucose concentrations were not significantly different between species (p=0.340), albumin glycation was significantly higher (p=0.004) in BAEA (23.67±1.90%) and BAOW (24.28±1.43%) compared to RTHA (14.31±0.63%). Of the antioxidants examined, lutein was significantly higher in BAOW (p=0.008). BAEA had the highest beta-cryptoxanthin and beta-carotene concentrations (p<0.005). The high concentrations of antioxidants in these birds of prey relative to other birds likely helps protect from complications that may otherwise arise from having high glucose and protein glycation.
Collapse
Affiliation(s)
- Tana Ingram
- School of Nutrition and Health Promotion, Arizona State University
| | - Jessica Zuck
- School of Nutrition and Health Promotion, Arizona State University
| | - Chad R Borges
- School of Molecular Sciences & The Biodesign Institute, Arizona State University, Tempe, AZ, United States
| | - Patrick Redig
- Raptor Center, College of Veterinary Medicine, University of Minnesota
| | - Karen L Sweazea
- School of Nutrition and Health Promotion, Arizona State University; School of Life Sciences, Arizona State University.
| |
Collapse
|
19
|
Paleari R, Bonetti G, Callà C, Carta M, Ceriotti F, Di Gaetano N, Ferri M, Guerra E, Lavalle G, Cascio CL, Martino FG, Montagnana M, Moretti M, Santini G, Scribano D, Testa R, Vero A, Mosca A. Multicenter evaluation of an enzymatic method for glycated albumin. Clin Chim Acta 2017; 469:81-86. [PMID: 28365449 DOI: 10.1016/j.cca.2017.03.028] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Accepted: 03/28/2017] [Indexed: 01/25/2023]
Abstract
BACKGROUND The use of glycated albumin (GA) has been proposed as an additional glycemic control marker particularly useful in intermediate-term monitoring and in situation when HbA1c test is not reliable. METHODS We have performed the first multicenter evaluation of the analytical performance of the enzymatic method quantILab Glycated Albumin assay implemented on the most widely used clinical chemistry analyzers (i.e. Abbott Architect C8000, Beckman Coulter AU 480 and 680, Roche Cobas C6000, Siemens ADVIA 2400 and 2400 XPT). RESULTS The repeatability of the GA measurement (expressed as CV, %) implemented in the participating centers ranged between 0.9% and 1.2%. The within-laboratory CVs ranged between 1.2% and 1.6%. A good alignment between laboratories was found, with correlation coefficients from 0.996 to 0.998. Linearity was confirmed in the range from 7.6 to 84.7%. CONCLUSION The new enzymatic method for glycated albumin evaluated by our investigation is suitable for clinical use.
Collapse
Affiliation(s)
- Renata Paleari
- Dip. di Fisiopatologia Medico-Chirurgica e dei Trapianti and Centro per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), Università degli Studi di Milano, Milano, Italy
| | - Graziella Bonetti
- Laboratorio Analisi Chimico Cliniche, ASST Spedali Civili, Brescia, Italy
| | - Cinzia Callà
- Polo Scienze delle Immagini, di Laboratorio ed Infettivologiche. Fondazione Policlinico Universitario A. Gemelli, Università Cattolica Sacro Cuore, Roma, Italy
| | | | - Ferruccio Ceriotti
- Central Laboratory, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - Nicola Di Gaetano
- Instrumentation Laboratory - A Werfen Company, R&D Department, Milano, Italy
| | - Marilisa Ferri
- Laboratorio Analisi di Urbino, Azienda Sanitaria Unica Regione Marche Area Vasta 1, Fano, PU, Italy
| | - Elena Guerra
- Laboratorio di Standardizzazione, Servizio Medicina di Laboratorio, Ospedale S. Raffaele, Milano, Italy
| | | | - Claudia Lo Cascio
- UOC Laboratorio Analisi, Azienda Ospedaliera Universitaria Integrata Verona, Italy
| | | | - Martina Montagnana
- Sezione di Biochimica Clinica, Dip. di Neuroscienze, Biomedicina e Movimento, Università degli Studi di Verona, Verona, Italy
| | - Marco Moretti
- Patologia Clinica Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro, Italy
| | - Gabriele Santini
- Instrumentation Laboratory - A Werfen Company, R&D Department, Milano, Italy
| | - Donata Scribano
- Polo Scienze delle Immagini, di Laboratorio ed Infettivologiche. Fondazione Policlinico Universitario A. Gemelli, Università Cattolica Sacro Cuore, Roma, Italy
| | - Roberto Testa
- Modelli di Integrazione Multidisciplinare in Patologia Clinica, INRCA-IRCCS, Ancona, Italy
| | - Anna Vero
- Laboratorio di Analisi Chimico-Clinica, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy
| | - Andrea Mosca
- Dip. di Fisiopatologia Medico-Chirurgica e dei Trapianti and Centro per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), Università degli Studi di Milano, Milano, Italy.
| |
Collapse
|
20
|
Zhou Q, Shi DB, Lv LY. The establishment of biological reference intervals of nontraditional glycemic markers in a Chinese population. J Clin Lab Anal 2016; 31. [PMID: 27859632 DOI: 10.1002/jcla.22097] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 10/23/2016] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND We established the reference intervals for glycated albumin (GA), fructosamine (FA), and 1,5-anhydroglucitol (1,5-AG) in a Chinese healthy population. METHODS This study enrolled a total of 458 eligible reference individuals, consisted of 226 men and 232 women, aged from 20~79 years (median age 43 years), who attending routine healthy checks. We stratified the subjects according to gender (males and females) and age (20-39, 40-59, and 60-79 years), and combined statistical methods with Lahti algorithm, as well as appropriate clinical consideration, to judge whether partitioning for data was needed. RESULTS Glycated albumin levels between males and females were statistically different (P<.001), but the absolute difference between the upper reference limits was only 0.31%, which was too small to be clinically relevant. GA levels across the three age groups were statistically different (P<.001), and Lahti algorithm suggested partitioning for 20-59 and 60-79 years, which reference intervals were 10.38%-13.89% and 10.23%-14.79%, respectively. 1,5-AG levels in males were significant higher than females (P<.001), and absolute difference was 51 μmol/L (8.5 μg/mL) in mean level. Thus, partitioning for gender was needed. Reference intervals for 1,5-AG were 107-367 μmol/L for males and 79-306 μmol/L for females. The absolute difference of the lower reference limits for FA was only 7 μmol/L between males and females. FA levels across the three age groups were not statistically different (P>.05). The reference interval for FA was 220-298 μmol/L. CONCLUSION New reference intervals for nontraditional glycemic markers were established based on a Chinese population.
Collapse
Affiliation(s)
- Qiang Zhou
- Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - De-Bao Shi
- Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Li-Ying Lv
- Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| |
Collapse
|
21
|
van den Berg SAA, de Groot MJM, Salden LPW, Draad PJGJ, Dijkstra IM, Lunshof S, van Thiel SW, Boonen KJM, Thelen MHM. Pregnancy diabetes: A comparison of diagnostic protocols based on point-of-care, routine and optimized laboratory conditions. Sci Rep 2015; 5:16302. [PMID: 26542612 PMCID: PMC4635356 DOI: 10.1038/srep16302] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2015] [Accepted: 10/09/2015] [Indexed: 12/16/2022] Open
Abstract
In vitro glycolysis poses a problem during diabetes screening, especially in remote laboratories. Point-of-care analysis (POC) may provide an alternative. We compared POC, routine and STAT analysis and a feasible protocol during glucose tolerance test (GTT) for pregnancy diabetes (GDM) screening. In the routine protocol, heparin tubes were used and turn-around-time (TAT) was unsupervised. In the STAT protocol, tubes were processed immediately. The feasible protocol comprised of citrated tubes with a TAT of 1 hour. Outcome was defined as glucose concentration and clinical diagnosis. Glucose measured by POC was higher compared to routine analysis at t = 0 (0.25 mM) and t = 120 (1.17 mM) resulting in 17% more GDM diagnoses. Compared to STAT analysis, POC glucose was also higher, although less pronounced (0.06 and 0.9 mM at t = 0 and t = 120 minutes, respectively) and misclassification was only 2%. Glucose levels and clinical diagnosis were similar using the feasible protocol and STAT analysis (0.03 mM and −0.07 mM at t = 0 and t = 120, 100% identical diagnoses). POC is an viable alternative for STAT glucose analysis in GDM screening (sensitivity: 100%, specificity: 98%). A feasible protocol (citrated phlebotomy tubes with a TAT of 60 minutes) resulted in 100% identical outcome and provides the best alternative.
Collapse
Affiliation(s)
| | | | - Lorenzo P W Salden
- Dept. of Clinical Chemistry and Hematology, Amphia Hospital, Breda, The Netherlands
| | - Patrick J G J Draad
- Dept. of Clinical Chemistry and Hematology, Amphia Hospital, Breda, The Netherlands
| | - Ineke M Dijkstra
- Dept. of Clinical Chemistry, Sint Anthonius Hospital, Nieuwegein, The Netherlands
| | - Simone Lunshof
- Dept. of Gynaecology, Amphia Hospital, Breda, The Netherlands
| | | | - Kristel J M Boonen
- Dept. of Clinical Chemistry and Hematology, Amphia Hospital, Breda, The Netherlands
| | - Marc H M Thelen
- Dept. of Clinical Chemistry and Hematology, Amphia Hospital, Breda, The Netherlands
| |
Collapse
|
22
|
Williams ME, Mittman N, Ma L, Brennan JI, Mooney A, Johnson CD, Jani CM, Maddux FW, Lacson E. The Glycemic Indices in Dialysis Evaluation (GIDE) study: Comparative measures of glycemic control in diabetic dialysis patients. Hemodial Int 2015; 19:562-71. [DOI: 10.1111/hdi.12312] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
| | - Neal Mittman
- Department of Dialysis; Kidney Care of Brooklyn and Queens; Brooklyn New York USA
| | - Lin Ma
- Department of Clinical Research; Fresenius Medical Care North America; Waltham Massachusetts USA
| | - Julia I. Brennan
- Department of Research; Spectra Laboratories; Rockleigh New Jersey USA
- Spectra Laboratories; Milpitas California USA
| | - Ann Mooney
- Department of Clinical Research; Fresenius Medical Care North America; Waltham Massachusetts USA
| | - Curtis D. Johnson
- Department of Research; Spectra Laboratories; Rockleigh New Jersey USA
- Spectra Laboratories; Milpitas California USA
| | - Chinu M. Jani
- Department of Research; Spectra Laboratories; Rockleigh New Jersey USA
- Spectra Laboratories; Milpitas California USA
| | - Franklin W. Maddux
- Department of Clinical Research; Fresenius Medical Care North America; Waltham Massachusetts USA
| | - Eduardo Lacson
- Department of Clinical Research; Fresenius Medical Care North America; Waltham Massachusetts USA
| |
Collapse
|
23
|
Danese E, Montagnana M, Nouvenne A, Lippi G. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol 2015; 9:169-76. [PMID: 25591856 PMCID: PMC4604592 DOI: 10.1177/1932296814567227] [Citation(s) in RCA: 100] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The efficient diagnosis and accurate monitoring of diabetic patients are cornerstones for reducing the risk of diabetic complications. The current diagnostic and prognostic strategies in diabetes are mainly based on two tests, plasma (or capillary) glucose and glycated hemoglobin (HbA1c). Nevertheless, these measures are not foolproof, and their clinical usefulness is biased by a number of clinical and analytical factors. The introduction of other indices of glucose homeostasis in clinical practice such as fructosamine and glycated albumin (GA) may be regarded as an attractive alternative, especially in patients in whom the measurement of HbA1c may be biased or even unreliable. These include patients with rapid changes of glucose homeostasis and larger glycemic excursions, and patients with red blood cell disorders and renal disease. According to available evidence, the overall diagnostic efficiency of GA seems superior to that of fructosamine throughout a broad range of clinical settings. The current method for measuring GA is also better standardized and less vulnerable to preanalytical variables than those used for assessing fructosamine. Additional advantages of GA over HbA1c are represented by lower reagent cost and being able to automate the GA analysis on many conventional laboratory instruments. Although further studies are needed to definitely establish that GA can complement or even replace conventional measures of glycemic control such as HbA1c, GA may help the clinical management of patients with diabetes in whom HbA1c values might be unreliable.
Collapse
Affiliation(s)
- Elisa Danese
- Department of Life and Reproduction Sciences, Laboratory of Clinical Biochemistry, University of Verona, Verona, Italy
| | - Martina Montagnana
- Department of Life and Reproduction Sciences, Laboratory of Clinical Biochemistry, University of Verona, Verona, Italy
| | - Antonio Nouvenne
- Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - Giuseppe Lippi
- Laboratory of Clinical Chemistry and Hematology, Academic Hospital of Parma, Parma, Italy
| |
Collapse
|
24
|
Abstract
Consumption of carbohydrate-containing foods leads to transient postprandial rises in blood glucose concentrations that vary between food types. Higher postprandial glycaemic exposures have particularly been implicated in the development of chronic cardiometabolic diseases. Reducing such diet-related exposures may be beneficial not only for diabetic patients but also for the general population. A variety of markers have been used to track different aspects of glycaemic exposures, with most of the relevant knowledge derived from diabetic patients. The assessment of glycaemic exposures among the non-diabetic population may require other, more sensitive markers. The present report summarises key messages of presentations and related discussions from a workshop organised by Unilever intended to consider currently applied markers of glycaemic exposure. The particular focus of the meeting was to identify the potential applicability of glycaemic exposure markers for studying dietary effects in the non-diabetic population. Workshop participants concluded that markers of glycaemic exposures are sparsely used in intervention studies among non-diabetic populations. Continuous glucose monitoring remains the optimal approach to directly assess glycaemic exposure. Markers of glycaemic exposure such as glycated Hb, fructosamine, glycated albumin, 1,5-anhydroglucitol and advanced glycation end products can be preferred dependent on the aspect of interest (period of exposure and glucose variability). For all the markers of glycaemia, the responsiveness to interventions will probably be smaller among the non-diabetic than among the diabetic population. Further validation and acceptance of existing glycaemic exposure markers applied among the non-diabetic population would aid food innovation and better design of dietary interventions targeting glycaemic exposure.
Collapse
|
25
|
The ratio of estimated average glucose to fasting plasma glucose level is superior to glycated albumin, hemoglobin A1c, fructosamine, and GA/A1c ratio for assessing β-cell function in childhood diabetes. BIOMED RESEARCH INTERNATIONAL 2014; 2014:370790. [PMID: 25013775 PMCID: PMC4071783 DOI: 10.1155/2014/370790] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Revised: 05/22/2014] [Accepted: 05/24/2014] [Indexed: 02/06/2023]
Abstract
Objective. This study investigated the use of the estimated average glucose to fasting plasma glucose ratio (eAG/fPG ratio) to screen for β-cell function in pediatric diabetes. Methods. Glycated hemoglobin (HbA1c), glycated albumin (GA), fructosamine, insulin, and C-peptide levels were measured. The ratio of GA to HbA1c (GA/A1c ratio) was calculated, and the homeostasis model assessment of β-cell function (HOMA-β) was determined. Results. Median values of C-peptide, insulin, and HOMA-β levels were significantly higher in patients with an increased eAG/fPG ratio than in those with a decreased eAG/fPG ratio. C-peptide and HOMA-β levels were more closely correlated with the eAG/fPG ratio than with GA, HbA1c, the GA/A1c ratio, and fructosamine. In contrast, body mass index was significantly associated with GA, GA/A1c ratio, and fructosamine, but not with the eAG/fPG ratio and HbA1c levels. To test the diagnostic accuracies of the eAG/fPG ratio for identifying HOMA-β > 30.0% in patients with type 2 diabetes, the area under the ROC curve of the eAG/fPG ratio was significantly larger than that of the GA/A1c ratio [0.877 (95% CI, 0.780–0.942) versus 0.775 (95% CI, 0.664–0.865), P = 0.039]. Conclusions. A measurement of the eAG/fPG ratio may provide helpful information for assessing β-cell function in pediatric patients with diabetes.
Collapse
|
26
|
|
27
|
[Assays of HbA1c and Amadori products in human biology]. ANNALES PHARMACEUTIQUES FRANÇAISES 2014; 72:330-6. [PMID: 25220229 DOI: 10.1016/j.pharma.2014.04.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 04/02/2014] [Accepted: 04/07/2014] [Indexed: 01/24/2023]
Abstract
Different Amadori products, formed during the early steps of the non-enzymatic glycation of proteins, may be assayed in current practice in human biology. The most important marker is HbA1c, resulting from the binding of glucose to the N-terminal extremity of HbA beta chains. HbA1c may be evaluated by various techniques (ion exchange or affinity high performance liquid chromatography, capillary electrophoresis, immunoassay, enzymatic technique) and is considered the best marker of diabetic patient survey. Due to its irreversible and cumulative formation, it provides a retrospective information on the glycemic balance over the four to eight weeks preceding blood collection. It benefits from an international standardization, based on a reference method using liquid chromatography coupled to capillary electrophoresis or mass spectrometry, maintained by an international network of reference laboratories. When HbA1c assay cannot be used (anemia, hemolysis, hemoglobinopathy) or when a shorter period of glycemic equilibrium must be evaluated (child and adolescent, pregnancy, therapeutic changes), other Amadori products may be assayed, like plasma fructosamine (all plasma glycated proteins) or glycated albumin. Nevertheless, these assays are less used in practice, because their semiological value has been less evidenced. Besides, fructosamine assay lacks specificity, and glycated albumin assay has been described recently. An expanding use of HbA1c assay is expected, especially for the diagnosis of diabetes mellitus and the evaluation of other risks, especially cardiovascular ones.
Collapse
|
28
|
Speeckaert M, Van Biesen W, Delanghe J, Slingerland R, Wiecek A, Heaf J, Drechsler C, Lacatus R, Vanholder R, Nistor I, Bilo H, Bolignano D, Couchoud C, Covic A, Coentrao L, Sutter JD, Drechsler C, Gnudi L, Goldsmith D, Heaf J, Heimburger O, Jager K, Nacak H, Nistor I, Soler M, Tomson C, Vanhuffel L, Biesen WV, Laecke SV, Weekers L, Wiecek A. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant 2014; 29:2167-77. [DOI: 10.1093/ndt/gfu006] [Citation(s) in RCA: 74] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|